BACKGROUND: Age-associated declines in muscle mass and function are major risk factors for an impaired ability to carry out activities of daily living, falls, prolonged recovery time after hospitalization, and mortality in older adults. New strategies that can slow the age-related loss of muscle mass and function are needed to help older adults maintain adequate performance status to reduce these risks and maintain independence. OBJECTIVE: We evaluated the efficacy of fish oil-derived n-3 (ω-3) PUFA therapy to slow the age-associated loss of muscle mass and function. DESIGN:Sixty healthy 60-85-y-old men and women were randomly assigned to receive n-3 PUFA (n = 40) or corn oil (n = 20) therapy for 6 mo. Thigh muscle volume, handgrip strength, one-repetition maximum (1-RM) lower- and upper-body strength, and average power during isokinetic leg exercises were evaluated before and after treatment. RESULTS:Forty-four subjects completed the study [29 subjects (73%) in the n-3 PUFA group; 15 subjects (75%) in the control group]. Compared with the control group, 6 mo of n-3 PUFA therapy increased thigh muscle volume (3.6%; 95% CI: 0.2%, 7.0%), handgrip strength (2.3 kg; 95% CI: 0.8, 3.7 kg), and 1-RM muscle strength (4.0%; 95% CI: 0.8%, 7.3%) (all P < 0.05) and tended to increase average isokinetic power (5.6%; 95% CI: -0.6%, 11.7%; P = 0.075). CONCLUSION:Fish oil-derived n-3 PUFA therapy slows the normal decline in muscle mass and function in older adults and should be considered a therapeutic approach for preventing sarcopenia and maintaining physical independence in older adults. This study was registered at clinicaltrials.gov as NCT01308957.
RCT Entities:
BACKGROUND: Age-associated declines in muscle mass and function are major risk factors for an impaired ability to carry out activities of daily living, falls, prolonged recovery time after hospitalization, and mortality in older adults. New strategies that can slow the age-related loss of muscle mass and function are needed to help older adults maintain adequate performance status to reduce these risks and maintain independence. OBJECTIVE: We evaluated the efficacy of fish oil-derived n-3 (ω-3) PUFA therapy to slow the age-associated loss of muscle mass and function. DESIGN: Sixty healthy 60-85-y-old men and women were randomly assigned to receive n-3 PUFA (n = 40) or corn oil (n = 20) therapy for 6 mo. Thigh muscle volume, handgrip strength, one-repetition maximum (1-RM) lower- and upper-body strength, and average power during isokinetic leg exercises were evaluated before and after treatment. RESULTS: Forty-four subjects completed the study [29 subjects (73%) in the n-3 PUFA group; 15 subjects (75%) in the control group]. Compared with the control group, 6 mo of n-3 PUFA therapy increased thigh muscle volume (3.6%; 95% CI: 0.2%, 7.0%), handgrip strength (2.3 kg; 95% CI: 0.8, 3.7 kg), and 1-RM muscle strength (4.0%; 95% CI: 0.8%, 7.3%) (all P < 0.05) and tended to increase average isokinetic power (5.6%; 95% CI: -0.6%, 11.7%; P = 0.075). CONCLUSION: Fish oil-derived n-3 PUFA therapy slows the normal decline in muscle mass and function in older adults and should be considered a therapeutic approach for preventing sarcopenia and maintaining physical independence in older adults. This study was registered at clinicaltrials.gov as NCT01308957.
Authors: John E Morley; Josep M Argiles; William J Evans; Shalender Bhasin; David Cella; Nicolaas E P Deutz; Wolfram Doehner; Ken C H Fearon; Luigi Ferrucci; Marc K Hellerstein; Kamyar Kalantar-Zadeh; Herbert Lochs; Neil MacDonald; Kathleen Mulligan; Maurizio Muscaritoli; Piotr Ponikowski; Mary Ellen Posthauer; Filippo Rossi Fanelli; Morrie Schambelan; Annemie M W J Schols; Michael W Schuster; Stefan D Anker Journal: J Am Med Dir Assoc Date: 2010-07 Impact factor: 4.669
Authors: Dennis T Villareal; Suresh Chode; Nehu Parimi; David R Sinacore; Tiffany Hilton; Reina Armamento-Villareal; Nicola Napoli; Clifford Qualls; Krupa Shah Journal: N Engl J Med Date: 2011-03-31 Impact factor: 91.245
Authors: Siew-Na Lim; Wenlong Huang; Jodie C E Hall; Rachael E Ward; John V Priestley; Adina T Michael-Titus Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2010-09-15 Impact factor: 4.006
Authors: Marko T Korhonen; Alexander Cristea; Markku Alén; Keijo Häkkinen; Sarianna Sipilä; Antti Mero; Jukka T Viitasalo; Lars Larsson; Harri Suominen Journal: J Appl Physiol (1985) Date: 2006-05-11
Authors: Gordon I Smith; Philip Atherton; Dominic N Reeds; B Selma Mohammed; Debbie Rankin; Michael J Rennie; Bettina Mittendorfer Journal: Am J Clin Nutr Date: 2010-12-15 Impact factor: 7.045
Authors: Robert D Boutin; Sara Bamrungchart; Cyrus P Bateni; Daniel P Beavers; Kristen M Beavers; John P Meehan; Leon Lenchik Journal: AJR Am J Roentgenol Date: 2017-03-07 Impact factor: 3.959
Authors: M Tieland; R Franssen; C Dullemeijer; C van Dronkelaar; H Kyung Kim; T Ispoglou; K Zhu; R L Prince; L J C van Loon; L C P G M de Groot Journal: J Nutr Health Aging Date: 2017 Impact factor: 4.075
Authors: Caoileann H Murphy; Ellen M Flanagan; Giuseppe De Vito; Davide Susta; Kathleen A J Mitchelson; Elena de Marco Castro; Joan M G Senden; Joy P B Goessens; Agnieszka Mikłosz; Adrian Chabowski; Ricardo Segurado; Clare A Corish; Sinead N McCarthy; Brendan Egan; Luc J C van Loon; Helen M Roche Journal: Am J Clin Nutr Date: 2021-06-01 Impact factor: 7.045
Authors: Stephan van Vliet; Gordon I Smith; Lane Porter; Raja Ramaswamy; Dominic N Reeds; Adewole L Okunade; Jun Yoshino; Samuel Klein; Bettina Mittendorfer Journal: J Physiol Date: 2018-08-29 Impact factor: 5.182
Authors: Nathalie Bakker; Rick S van den Helder; Remy W F Geenen; Michiel A Hunfeld; Huib A Cense; Ahmet Demirkiran; Alexander P J Houdijk Journal: Obes Surg Date: 2019-07 Impact factor: 4.129